{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:57:25Z","timestamp":1791496645173,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Brain Tumor Charity"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Management of clinically aggressive meningiomas is a considerable challenge. PD-L1 induced immune suppression has increasingly gained attention in clinical management of cancer; however, to date, the clinical significance and regulatory mechanisms of PD-L1 in meningioma is not yet fully characterized. We sought to characterize PD-L1 expression in meningioma and elucidate its regulatory mechanisms. Immunohistochemical staining of PD-L1 expression in meningiomas showed 43% positivity in both tumor and immune cells and we observed intra and inter tumoral heterogeneity. Univariate and multivariate analyses confirmed that PD-L1 protein expression is an independent prognostic marker for worse recurrence free survival in meningioma. Furthermore, our transcriptomic analysis revealed a strong association between PD-L1 expression and that of NFKB2 and carbonic anhydrase 9 (CA9). We also demonstrated that both of these markers, when co-expressed with PD-L1, predict tumor progression. Our studies on several meningioma cell lines cultured in hypoxic conditions validated the association of CA9 and PD-L1 expression. Here we show the clinical significance of PD-L1 in meningioma as a marker that can predict tumor recurrence. We also show an association PD-L1 expression with NFKB2 expression and its induction under hypoxic conditions. These findings may open new avenues of molecular investigation in pathogenesis of meningioma.<\/jats:p>","DOI":"10.1038\/s41598-020-70514-z","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T06:04:26Z","timestamp":1598249066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression"],"prefix":"10.1038","volume":"10","author":[{"given":"Shirin","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Mamatjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Nassiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suganth","family":"Suppiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Aldape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelareh","family":"Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,24]]},"reference":[{"key":"70514_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","volume":"19","author":"QT Ostrom","year":"2017","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014. Neuro Oncol. 19, v1\u2013v88. https:\/\/doi.org\/10.1093\/neuonc\/nox158 (2017).","journal-title":"Neuro Oncol."},{"key":"70514_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3171\/2014.7.JNS131644","volume":"122","author":"L Rogers","year":"2015","unstructured":"Rogers, L. et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J. Neurosurg. 122, 4\u201323. https:\/\/doi.org\/10.3171\/2014.7.JNS131644 (2015).","journal-title":"J. Neurosurg."},{"key":"70514_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2990.2004.00621.x","volume":"31","author":"J Willis","year":"2005","unstructured":"Willis, J. et al. The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol. Appl. Neurobiol. 31, 141\u2013149. https:\/\/doi.org\/10.1111\/j.1365-2990.2004.00621.x (2005).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"70514_CR4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark, V. E. et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339, 1077\u20131080. https:\/\/doi.org\/10.1126\/science.1233009 (2013).","journal-title":"Science"},{"key":"70514_CR5","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ng.3651","volume":"48","author":"VE Clark","year":"2016","unstructured":"Clark, V. E. et al. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat. Genet. 48, 1253\u20131259. https:\/\/doi.org\/10.1038\/ng.3651 (2016).","journal-title":"Nat. Genet."},{"key":"70514_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm, F. et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 18, 682\u2013694. https:\/\/doi.org\/10.1016\/S1470-2045(17)30155-9 (2017).","journal-title":"Lancet Oncol."},{"key":"70514_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz061","author":"F Nassiri","year":"2019","unstructured":"Nassiri, F. et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noz061 (2019).","journal-title":"Neuro Oncol."},{"key":"70514_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330. https:\/\/doi.org\/10.1038\/nature21349 (2017).","journal-title":"Nature"},{"key":"70514_CR9","doi-asserted-by":"publisher","first-page":"13866","DOI":"10.1073\/pnas.231486598","volume":"98","author":"T Okazaki","year":"2001","unstructured":"Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. & Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. U. S. A. 98, 13866\u201313871. https:\/\/doi.org\/10.1073\/pnas.231486598 (2001).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"70514_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.trsl.2018.05.011","volume":"202","author":"S Kumar","year":"2018","unstructured":"Kumar, S. & Sharawat, S. K. Epigenetic regulators of programmed death-ligand 1 expression in human cancers. Transl. Res. 202, 129\u2013145. https:\/\/doi.org\/10.1016\/j.trsl.2018.05.011 (2018).","journal-title":"Transl. Res."},{"key":"70514_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434\u2013452. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014 (2018).","journal-title":"Immunity"},{"key":"70514_CR12","doi-asserted-by":"publisher","first-page":"175883591881559","DOI":"10.1177\/1758835918815598","volume":"10","author":"FP Fabrizio","year":"2018","unstructured":"Fabrizio, F. P. et al. Gene code CD274\/PD-L1: from molecular basis toward cancer immunotherapy. Ther. Adv. Med. Oncol. 10, 1758835918815598. https:\/\/doi.org\/10.1177\/1758835918815598 (2018).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"70514_CR13","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","volume":"41","author":"X Meng","year":"2015","unstructured":"Meng, X., Huang, Z., Teng, F., Xing, L. & Yu, J. Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy. Cancer Treat. Rev. 41, 868\u2013876. https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.001 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"70514_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang, X. et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol. Cancer 18, 10. https:\/\/doi.org\/10.1186\/s12943-018-0928-4 (2019).","journal-title":"Mol. Cancer"},{"key":"70514_CR15","doi-asserted-by":"publisher","first-page":"e1512943","DOI":"10.1080\/2162402X.2018.1512943","volume":"8","author":"DT Proctor","year":"2019","unstructured":"Proctor, D. T. et al. Identification of PD-L2, B7\u2013H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma. Oncoimmunology 8, e1512943. https:\/\/doi.org\/10.1080\/2162402X.2018.1512943 (2019).","journal-title":"Oncoimmunology"},{"key":"70514_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11060-016-2256-0","volume":"130","author":"SJ Han","year":"2016","unstructured":"Han, S. J. et al. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J. Neurooncol. 130, 543\u2013552. https:\/\/doi.org\/10.1007\/s11060-016-2256-0 (2016).","journal-title":"J. Neurooncol."},{"key":"70514_CR17","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.18632\/oncotarget.3082","volume":"6","author":"Z Du","year":"2015","unstructured":"Du, Z. et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget 6, 4704\u20134716. https:\/\/doi.org\/10.18632\/oncotarget.3082 (2015).","journal-title":"Oncotarget"},{"key":"70514_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2015.07.019","volume":"53","author":"P Domingues","year":"2016","unstructured":"Domingues, P. et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav. Immun. 53, 1\u201315. https:\/\/doi.org\/10.1016\/j.bbi.2015.07.019 (2016).","journal-title":"Brain Behav. Immun."},{"key":"70514_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00190","author":"IF Dunn","year":"2018","unstructured":"Dunn, I. F. et al. Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.18.00190 (2018).","journal-title":"JCO Precis. Oncol."},{"key":"70514_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/jclinpath-2017-204525","volume":"71","author":"T El Jabbour","year":"2018","unstructured":"El Jabbour, T. et al. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. J. Clin. Pathol. 71, 46\u201351. https:\/\/doi.org\/10.1136\/jclinpath-2017-204525 (2018).","journal-title":"J. Clin. Pathol."},{"key":"70514_CR21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jtho.2018.04.017","volume":"13","author":"E Munari","year":"2018","unstructured":"Munari, E. et al. PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsy specimens and whole sections. J. Thorac. Oncol. 13, 1113\u20131120. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.017 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"70514_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13000-018-0689-9","volume":"13","author":"M Udall","year":"2018","unstructured":"Udall, M. et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn. Pathol. 13, 12. https:\/\/doi.org\/10.1186\/s13000-018-0689-9 (2018).","journal-title":"Diagn. Pathol."},{"key":"70514_CR23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1750-3639.2009.00356.x","volume":"20","author":"Y Lee","year":"2010","unstructured":"Lee, Y. et al. Genomic landscape of meningiomas. Brain Pathol. 20, 751\u2013762. https:\/\/doi.org\/10.1111\/j.1750-3639.2009.00356.x (2010).","journal-title":"Brain Pathol."},{"key":"70514_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1158\/0008-5472.CAN-07-1796","volume":"68","author":"EB Claus","year":"2008","unstructured":"Claus, E. B., Park, P. J., Carroll, R., Chan, J. & Black, P. M. Specific genes expressed in association with progesterone receptors in meningioma. Cancer Res. 68, 314\u2013322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1796 (2008).","journal-title":"Cancer Res."},{"key":"70514_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jocn.2018.08.023","volume":"57","author":"MD Johnson","year":"2018","unstructured":"Johnson, M. D. PD-L1 expression in meningiomas. J. Clin. Neurosci. 57, 149\u2013151. https:\/\/doi.org\/10.1016\/j.jocn.2018.08.023 (2018).","journal-title":"J. Clin. Neurosci."},{"key":"70514_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1146\/annurev.immunol.14.1.649","volume":"14","author":"AS Baldwin Jr","year":"1996","unstructured":"Baldwin, A. S. Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649\u2013683. https:\/\/doi.org\/10.1146\/annurev.immunol.14.1.649 (1996).","journal-title":"Annu. Rev. Immunol."},{"key":"70514_CR27","doi-asserted-by":"publisher","first-page":"e61602","DOI":"10.1371\/journal.pone.0061602","volume":"8","author":"G Huang","year":"2013","unstructured":"Huang, G., Wen, Q., Zhao, Y., Gao, Q. & Bai, Y. NF-kappaB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS ONE 8, e61602. https:\/\/doi.org\/10.1371\/journal.pone.0061602 (2013).","journal-title":"PLoS ONE"},{"key":"70514_CR28","doi-asserted-by":"publisher","first-page":"e1423170","DOI":"10.1080\/2162402X.2017.1423170","volume":"7","author":"A Asgarova","year":"2018","unstructured":"Asgarova, A. et al. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology 7, e1423170. https:\/\/doi.org\/10.1080\/2162402X.2017.1423170 (2018).","journal-title":"Oncoimmunology"},{"key":"70514_CR29","doi-asserted-by":"publisher","first-page":"C569","DOI":"10.1152\/ajpcell.00207.2015","volume":"309","author":"MZ Noman","year":"2015","unstructured":"Noman, M. Z. et al. Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. Am. J. Physiol. Cell. Physiol. 309, C569\u2013C579. https:\/\/doi.org\/10.1152\/ajpcell.00207.2015 (2015).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"70514_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen, J., Jiang, C. C., Jin, L. & Zhang, X. D. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol. 27, 409\u2013416. https:\/\/doi.org\/10.1093\/annonc\/mdv615 (2016).","journal-title":"Ann. Oncol."},{"key":"70514_CR31","doi-asserted-by":"publisher","first-page":"e1358332","DOI":"10.1080\/2162402X.2017.1358332","volume":"6","author":"DJ Pinato","year":"2017","unstructured":"Pinato, D. J. et al. Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: relationship with the hypoxic response, immune evasion and malignant behavior. Oncoimmunology 6, e1358332. https:\/\/doi.org\/10.1080\/2162402X.2017.1358332 (2017).","journal-title":"Oncoimmunology"},{"key":"70514_CR32","doi-asserted-by":"publisher","first-page":"e1108514","DOI":"10.1080\/2162402X.2015.1108514","volume":"5","author":"J Koh","year":"2016","unstructured":"Koh, J. et al. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1alpha and STAT3. Oncoimmunology 5, e1108514. https:\/\/doi.org\/10.1080\/2162402X.2015.1108514 (2016).","journal-title":"Oncoimmunology"},{"key":"70514_CR33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781\u2013790. https:\/\/doi.org\/10.1084\/jem.20131916 (2014).","journal-title":"J. Exp. Med."},{"key":"70514_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/1078-0432.CCR-06-1377","volume":"13","author":"H Yoo","year":"2007","unstructured":"Yoo, H. et al. Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin. Cancer Res. 13, 68\u201375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1377 (2007).","journal-title":"Clin. Cancer Res."},{"key":"70514_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1227\/NEU.0b013e3182567886","volume":"71","author":"R Jensen","year":"2012","unstructured":"Jensen, R. & Lee, J. Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation. Neurosurgery 71, 146\u2013156. https:\/\/doi.org\/10.1227\/NEU.0b013e3182567886 (2012).","journal-title":"Neurosurgery"},{"key":"70514_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3171\/2016.10.JNS161825","volume":"128","author":"M Karsy","year":"2018","unstructured":"Karsy, M., Burnett, B., Di Ieva, A., Cusimano, M. D. & Jensen, R. L. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome. J. Neurosurg. 128, 657\u2013666. https:\/\/doi.org\/10.3171\/2016.10.JNS161825 (2018).","journal-title":"J. Neurosurg."},{"key":"70514_CR37","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1111\/nan.12166","volume":"41","author":"S Jalali","year":"2015","unstructured":"Jalali, S. et al. A role for matrix remodelling proteins in invasive and malignant meningiomas. Neuropathol. Appl. Neurobiol. 41, e16\u2013e28. https:\/\/doi.org\/10.1111\/nan.12166 (2015).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"70514_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1227\/00006123-199009000-00008","volume":"27","author":"WH Lee","year":"1990","unstructured":"Lee, W. H. Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery 27, 389\u2013395 (1990) (discussion 396).","journal-title":"Neurosurgery"},{"key":"70514_CR39","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3171\/jns.1995.82.5.0864","volume":"82","author":"JC Tsai","year":"1995","unstructured":"Tsai, J. C., Goldman, C. K. & Gillespie, G. Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J. Neurosurg. 82, 864\u2013873. https:\/\/doi.org\/10.3171\/jns.1995.82.5.0864 (1995).","journal-title":"J. Neurosurg."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70514-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70514-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70514-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:38:01Z","timestamp":1670330281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-70514-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,24]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["70514"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-70514-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,24]]},"assertion":[{"value":"23 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14115"}}